Ultragenyx Pharmaceutical (RARE) Net Income towards Common Stockholders Growth (5y) (2018 - 2026)
Ultragenyx Pharmaceutical (RARE) Net Income towards Common Stockholders Growth (5y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ultragenyx Pharmaceutical | 2.77 Bn | 2.36 Bn | 106.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.33% |
| Dec 31, 2025 | -39.87% |
| Sep 30, 2025 | -21.25% |
| Jun 30, 2025 | -45.59% |
| Mar 31, 2025 | -4.87% |
| Dec 31, 2024 | 45.72% |
| Sep 30, 2024 | -3.39% |
| Jun 30, 2024 | -5.82% |
| Mar 31, 2024 | -12.02% |
| Dec 31, 2023 | -7.06% |
| Sep 30, 2023 | -12.83% |
| Jun 30, 2023 | -24.83% |
| Mar 31, 2023 | -49.31% |
| Dec 31, 2022 | -9.39% |
| Sep 30, 2022 | -25.34% |
| Jun 30, 2022 | -16.76% |
| Mar 31, 2022 | -17.40% |
| Dec 31, 2021 | -11.86% |
| Sep 30, 2021 | -2.38% |
| Jun 30, 2021 | -16.55% |